Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.

Slides:

Advertisements

Similar presentations

Neoadjuvant therapy for Rectal cancer

Advertisements

Multimodality Therapy of Rectal Cancer Robert D. Madoff, MD University of Minnesota.

Rectal Cancer: A Complete Clinical Response…Now what?

JHSGR Neoadjuvant Therapy For Rectal Cancer Dr Chris TL Cheng Princess Margaret Hospital.

Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.

Clinicopathologic Characteristics and Predictors of Outcomes in Patients with Primary Retroperitoneal Dedifferentiated Liposarcoma Undergoing Surgery Emily.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Abstract Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer A. Cercek, K.

Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.

Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.

A Propensity-matched Study of Lobectomy Versus Segmentectomy for Radiologically Pure Solid Small-sized Non-small Cell Lung Cancer Terumoto Koike 1, Seijiro.

PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;

Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.

Neoadjuvant Chemotherapy for Ca Breast CY Choi UCH.

Management of Locally Advanced Rectal Cancer Joint Hospital Surgical Grand Round Pamela Youde Nethersole Eastern Hospital Dr. YH Ling 19 May 2007.

THE SIGNIFICANCE OF HISTOLOGICAL SUBSTAGING IN CURATIVE RESECTED T3 COLORECTAL CANCER Karl Mrak & Jörg Tschmelitsch Department of Surgery, Barmherzige.

Prospective Phase II Study of Preoperative Radiotherapy and Oral Capecitabine followed by Total Mesorectal Exicision (TME) in Locally Advanced Rectal Cancer.

Clinical Outcomes and Patterns of Failure in Pineoblastoma: A 30-year Single Institution Experience Benjamin Farnia, B.A. ASTRO Poster Discussion September.

Skull Base Chordoma and Chondrosarcoma: Changes in National Radiotherapy Patterns and Survival Outcomes Henry S. Park, MD, MPH; Kenneth B. Roberts, MD;

Brendan Moran Basingstoke OCTOBER 2008

Failure of Treatment in Cervical Cancer Patients *Dr. Zohreh Yousefi fellow ship of gynecology oncology of Mashhad university Fatemeh Homaee, Marzieh.

Lymphadenectomy in Epithelial Ovarian Cancer

Multimodality therapy for locally advanced thymomas: a cohort study of prognostic factors from a European multicentric database Dr. GIOVANNI LEUZZI Department.

Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.

Postoperative Radiotherapy for Patients with Stage II or III Nonsmall Cell Lung Cancer treated with Sublobar Resections: A SEER Registry Analysis Scott.

What is the Preferable Treatment Option for T1/T2 Low Rectal Cancer? Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology.

Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,

CR07 results and informed patient consent David Sebag-Montefiore Leeds Cancer Centre.

Preoperative chemoradiotherapy and postoperative chemotherapy with 5-FU and oxaliplatin versus 5-FU alone in locally advanced rectal cancer: First results.

Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from.

“small” T3 short-term RT and TME “large” T3 long-term CRT and TME T4 long term CRT and TME Therefore: tailored treatment.

Ductal Carcinoma in Situ with Microinvasion: Prognostic Implications, Long-term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, MD 1, Bruce.

Accuracy of EUS in diagnosis of rectal cancer KKUH experience

AUDIT OF DOWN-STAGING CHEMORADIATION FOR LOCALLY ADVANCED RECTAL CANCER DR J J NICOLL NORTH CUMBRIA UNIVERSITY HOSPITALS SEPTEMBER 2012.

Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,

THE EFFECT OF AGE ON OUTCOME OF SYNOVIAL SARCOMA PATIENTS A DUTCH POPULATION BASED STUDY Myrella Vlenterie, SEJ Kaal, VKY Ho, R Vlenterie, WTA van der.

PRE-OPERATIVE STAGING OF RECTAL CANCER: THE SIGNIFICANCE OF FAT STREAKING ON COMPUTED TOMOGRAPHY E Leung, J Francombe Warwick Hospital, Lakin Road, Warwick,

FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,

Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of the stomach and lower.

Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy Mitsui Memorial Hospital Department of Breast and.

Mamoun A. Rahman Surgical SHO Mr Osborne’s team. Introduction Blood transfusion: -Preoperative ( elective) -Intra/postoperative ( urgent) Blood transfusion.

Radical surgery is the preferable treatment option for T1- 2/N0 low rectal cancer Jose G. Guillem, MD, MPH Department of Surgery Memorial Sloan Kettering.

Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial Short course pre-op vs selective post-op chemo-RT for rectal cancer Local Recurrence after.

Role of Sentinel Lymph Node Biopsy in the Staging of Synovial, Epithelioid, and Clear Cell Sarcomas. Ugwuji N. Maduekwe, Francis J. Hornicek, Dempsey S.

Dr Mark Saunders Christie Hospital and Paterson Institute of Cancer Research “ Rectal cancer radiotherapy – why do we give it and how do we do it?”

Basingstoke Colorectal The Particular Problem of Low Rectal Cancer Brendan Moran Basingstoke 4 th East-West Colorectal Days Hungary 2008.

Role of MRI in Primary Rectal Cancer Staging and Management

Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.

What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,

Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.

Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.

Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada JOURNAL OF CLINICAL ONCOLOGY, VOLUME 30.

Javier Martin-Broto, Silvia Calabuig, Jordi Rubió, Antonio Gutierrez, José Duran, Florencia García, Javier Martinez Trufero, Joan Maurel, Xavier García.

Rectal Cancer MOTP Half Day September 9, 2008

Evaluating the Clinical Outcomes of Sixty-Three Patients Treated with Gamma Knife as Salvage Therapy for Glioblastoma Multiforme Erik W Larson, Halloran.

ABSTRACT Purpose This retrospective review was conducted to determine if delay in the start of radiotherapy after conservative breast surgery had any detrimental.

RECTAL CARCINOMA AND PREOPERATIVE MRI: USING A NATIONAL DATASET FOR REGIONAL AUDIT South West Cancer Intelligence Service J Weeks

Staging of rectal cancer by EUS: depth of infiltration in T3 cancers is important Christian Jürgensen, MD, Andreas Teubner, MD, Jörg-Olaf Habeck, MD, Friederike.

Karcinom rektuma- management

Operative Approach and

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

Dr Jessica Jenkins Consultant Oncologist

Effect of Neoadjuvant Concurrent Chemoradiotherapy on Locally Advanced Middle and Low Rectal Cancer— A Propensity Score Matching Study 官泰全,林春吉,楊純豪,姜正愷,林宏鑫,藍苑慈,

Do all patients with T2-3 mid-high rectal adenocarcinomas require RT as part of their neoadjuvant therapy? - Yes -   Bruce Minsky.

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,

Treated with Neoadjuvant Therapy

The SUV on 18F-FDG-PET/CT imaging as an independent predictor for overall survival and disease free survival after hepatectomy of Hepatocellular carcinoma（

Presentation transcript:

Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E. García-Granero 2, S. Roselló 1, B. Flor 2, E. Rodríguez 1, P. Esclapez 2, S. Campos 3, S. García- Botello 2, A. Cervantes 1. Department of Hematology Medical Oncology1, Colorectal Unit, Department of Surgery2, INCLIVA, University of Valencia, Valencia, Spain. Abstract # 50936

Abstract Background: Preop CRT is becoming the standard of care for patients with locally advanced RC. However, since the introduction of total mesorectal excision (TME), local recurrence rates are significantly reduced and some pts can be spared from a potentially toxic overtreatment. Preop staging with magnetic resonance imaging (MRI) and/or endorectal ultrasonography (ERUS) may help in selecting pts for preop CRT. This retrospective study was designed to assess factors predicting recurrence in an institutional series of RC pts with clinical stage T2N+, T3N0/+, treated by radical surgery without preop CRT. Methods: Between Nov 1997 to Nov 2008, our multidisciplinary group staged preop 398 RC patients by ERUS and/or MRI. We selected for this analysis 154 consecutive pts, having uT2N+, uT3N0, and uT3N+ rc, who didn’t get preop CRT. Macroscopical assessment of mesorectal excision and microscopic study of all circumferential resection margins (CRM) was determined. Factors potentially related with local recurrence (LR), Disease free survival (DFS) and overall survival (OS) were studied. Results: Median follow-up was 34 months (range, 18 to 68,2 months). LR rate was 8.5%, and 5-year DFS and OS were respectively 64.5% and 75.4% for the whole group. Threatened mesorectal fascia at preop staging, defined as tumor located at < 2 mm, was seen in 19 patients and was the most powerful single factor to predict a higher risk for LR, shorter DFS and worse OS. Other factors such as preop N+ or location of the tumor did not predict the risk of LR. Conclusions: Threatening of mesorectal fascia as defined preoperative by US or MRI, was the only significant factor predicting LR as well as worse DFS and OS. RC pts clinically staged as T3N0/+ or T2N+ > 2 mm away from mesorectal fascia could be treated with TME alone with a risk of LR of less than 5%, and overtreatment with preop CRT could be avoided. Abstract # 50936

Background Preop CRT is becoming the standard of care for patients with locally advanced RC. However, since the introduction of total mesorectal excision (TME), local recurrence rates are significantly reduced and some pts can be spared from a potentially toxic overtreatment. Preop staging with magnetic resonance imaging (MRI) and/or endorectal ultrasonography (ERUS) may help in selecting pts for TME surgery alone.

This retrospective study was designed to assess factors predicting local and overall recurrence in an institutional serie of RC pts with clinical stage T2N+, T3N0/+, treated by radical TME surgery without preoperative CRT. Purpose

Methods: Between Nov 1997 to Nov 2008, our multidisciplinary group staged preop 398 RC patients by ERUS and/or MRI in a single institution. We selected for this analysis 154 consecutive pts, having cT2N+, cT3N0, and cT3N+ RC, who didn’t get preop CRT. TME was performed in all patients. Standard pathologic analysis was performed on all resection specimens: macroscopical assessment of mesorectal excision and microscopic study of all circumferential resection margins (CRM) was determined.

Factors potentially related with local recurrence (LR), disease free survival (DFS) and overall survival (OS) were studied. Statistical analysis included  2 test for prognostic variables. Univariate analysis of survival were carried out by the Kaplan-Meier Method. A Cox multivariate survival analysis was performed with factors found to be statistically significant on the univariate analysis. Methods:

398 RC pts evaluated with ERUS and/or MRI 350 pts with cT2N+ or cT3 rectal cancer cT1 :4 pts cT2N0 : 20 ptsc T4 : 24 pts 160 patients treated with preoperative CRT 190 pts operated without preoperative CRT 36 pts M1 154 pts with R0 or R1 resection Figure 1- Selection of patients

Median Age (range) 70 (38-90) Sex Male94 (61%) Female60 (39%) Tumor Location Upper rectum17 (11%) Medium rectum55 (35,7%) Lower rectum82 (53,2%) Preop staging Only ERUS77 (50,0%) Only MRI15 (9,74%) ERUS and MRI62 (40,26%) Preop CRM Free111 (72,1%) Threatened19 (12,3%) No Evaluable24 (15,6%) Surgical Procedure Miles' procedure42 (27,3%) Sphincter saving procedure112 (72,7%) Post-op Mortality 6 (3,9%) Quality mesorectum Complete77 (50,0%) Nearly Complete26 (16,88%) Incomplete9 (5,85%) Not evaluated42 (27,27%) Post-Op Therapy CT+RT3 (2%) CT34 (22,1%) Table 1. Patients characteristics

Results Median follow-up was 39 months (range, 18 to 152 months). 5-year actuarial LR rate, DFS OS9.5%64.5%75.4%For the whole group, 5-year actuarial LR rate, DFS and OS were 9.5% 64.5% and 75.4% respectively. Different preoperative factors were studied as predictors of recurrence : treatened vs free fascia preoperative nodal status surgery (Miles' procedure vs sphincter saving procedure) tumor location.

Results Threatened mesorectal fascia at preop staging, defined as tumor located at < 2 mm, was seen in 19 patients and was the most powerful single factor to predict a higher risk for LR, shorter DFS and worse OS. (fig 1 and 2).

Results Crude Rate (%) Hazard Ratio 95% CIP value Preoperative CRM Threatened or not evaluable vs. free fascia LR 21 vs DFS 63.1 vs OS 73.6 vs Patological CRM Affected vs. free fascia LR 28.0 vs < DFS 40.0 vs 80.64, < OS 52.0 vs < Patological N N+ vs N- LR 19.5 vs DFS 54.7 vs < OS 66.5 vs < Table 3. Univariate analysis for LR, DFS, and OS Table 3. Univariate analysis for LR, DFS and OS. Pathological CRM and nodal status were studied as predictors of recurrence. In a univariate analysis both were significant predictors of LR, DFS and OS (Table 3).

Results Hazar d Ratio 95% CIP value Patological CRM Affected vs. free fascia LR DFS2, OS Patological N N+ vs N- LR DFS OS However, in a multivariate Cox regression analysis, only involved CRM resulted as an independent predictor of LR, while both were independent predictors of DFS and OS (Table 4). Table 4. Multivariate analysis for LR, DFS and OS.

pN- (n) pN+ (n) Total (n) Overstaged (%) Undesrtaged (%) Accuracy (%) cN ,878,2 cN ,8-53,2 cNx Total ,67,860,4 Results Table 2. Preoperative N staging vs Pathologic N examination

Threatening of mesorectal fascia as defined preoperatively by ERUS or MRI, was the only preop significant factor predicting higher risk for LR as well as worse DFS and OS. RC pts clinically staged as T3N0/+ or T2N+ > 2 mm away from mesorectal fascia could be treated with TME alone with a risk of LR of less than 5%, and overtreatment with preop CRT could be avoided. To improve accuracy of preop staging may help in better selection of RC patients preoperative treatment. Conclusions: